Keyphrases
Autologous Tumors
12%
Cas9 Protein
12%
CD4+
100%
CD4+ T
12%
CD4+ T Cells
12%
Cell Response
12%
CIITA
12%
Clinical Outcomes
12%
Clustered Regularly Interspaced Short Palindromic repeats/Cas9
12%
Cytotoxic Activity
12%
Cytotoxicity
50%
Drug-resistant Tumor
62%
Gene Editing
12%
Gene Knockout
12%
IFN Signaling
25%
Immune Checkpoint Blockade
62%
Immune Effector Molecules
12%
JAK Signaling
100%
Melanoma
100%
Melanoma Cells
12%
MHC Class II
12%
MHC Class II Expression
12%
MHC Class II Molecules
12%
Overcoming Resistance
12%
Patient-specific
12%
Tumor
12%
Tumor Cells
12%
Tumor Killing
100%
Tumor Phenotype
12%
Tumor-infiltrating Lymphocytes
100%
Tumor-specific
37%
β2-microglobulin (β2-MG)
12%
Medicine and Dentistry
Cas9
12%
Cell Mediated Cytotoxicity
50%
Clustered Regularly Interspaced Short Palindromic Repeat
12%
Epileptic Absence
12%
Gene Knockout
12%
Immune Checkpoint Blockade
62%
Immunotherapy
12%
Infusion
12%
Melanoma Cell Line
12%
Neoplasm
100%
Nodular Melanoma
100%
Specific Tumor
37%
T-Cell Response
12%
T-Helper Cell
25%
Tumor Cell
12%
Tumor Infiltrating Lymphocyte
100%
Upregulation
12%
Immunology and Microbiology
CD4
100%
CIITA
11%
Clustered Regularly Interspaced Short Palindromic Repeat
11%
Cytotoxicity
44%
Gene Editing
11%
Gene Knockout
11%
Immune Checkpoint Blockade
55%
Immunotherapy
11%
Melanoma Cell Line
11%
MHC Class II
22%
T-Helper Cell
22%
Tumor Cell
11%
Tumor-Infiltrating Lymphocytes
100%
Upregulation
11%
Biochemistry, Genetics and Molecular Biology
Cas9
9%
CD4
100%
CIITA
9%
CRISPR
9%
Cytotoxicity
36%
Gene Knockout
9%
Genome Editing
9%
Immune Checkpoints
45%
MHC Class II
18%
Microglobulin
9%
T Cell
18%
Tumor-Infiltrating Lymphocytes
100%
Upregulation
9%